Germany Program · 2019-05-23 · Program P215 1-5/2019/1.100 Stü ... Igor will forever remain a...

Symposium 215

IBD: From Diagnosis to Therapy

July 5–6, 2019Park Inn by RadissonPribaltiyskayaSt. Petersburg, Russia

Program

P215

1-5

/201

9/1

.10

0 St

ü

Application for CME credits submitted

Organized by:

FALK FOUNDATION e.V.Leinenweberstr. 579108 FreiburgGermany

Congress DepartmentTel.: +49–761–1514–125Fax: +49–761–1514–359E-Mail: symposia@falk-foundation-symposia.orgwww.falk-foundation-symposia.org

20414_Falk_St_Petersburg_Symp_215_Prog_UG.indd 1 20.05.19 09:55

3

Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4

Scientific Program . . . . . . . . . . . . . . . . . . . . . . . . . 6

Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

List of Speakers, Moderators and Scientific Organizers . . . . . . . . . . . . . . . . . . . . . . . 18

Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22

CME credits for the Symposium 215 have been applied for at the European Union of Medical Specialists (UEMS) . You will receive your certificate at the registration desk .

20414_Falk_St_Petersburg_Symp_215_Prog_Inhalt.indd 3 21.05.19 09:44

4

ObituaryDear Friends and Colleagues!February 18, 2019, the Russian IBD Study society and the entire medical community of Russia suffered an irreparable loss. Professor Igor Khalif, Head of the Department of Inflammatory and Functional Bowel Diseases of Russian State Center of Coloproctology died after a serious illness.It is a great grief and a huge pain not only for his family and friends, but for all his colleagues and like-minded people, not only in Russia, but abroad. After graduating from the Medical University his clinical practice and research interests were associated with the above Center, where he has grown from a clinical resident to the Head of a large department.For the past 30 years his research interests have been linked with inflammatory bowel diseases. He left us still at an active creative age. An important area of his scientific activity was the introduction and improvement of new methods of treatment of these diseases, the development of methodological approaches; he became the author and co-author of a large number of publications and monographs. Professor Igor Khalif was a member of Guidelines Committee of WGO. He was one of the active organizers of the Russian IBD Study Society and was its permanent chairman or co-chair. He actively promoted ECCO ideas in Russian clinical practice, took an active part in the organization of ECCO workshops and international IBD conferences in Russia and developed Russian IBD guidelines. He was member of the organizing committee of this Symposium in St. Petersburg to which program he contributed with vigor and his unique skill to see the demands of Russian physicians reflected. Igor had excellent leadership qualities. His unstoppable energy and unique communication skills contributed to contacts between Russian physicians and colleagues from many other nationalities. Igor succeeded to connect people in friendship. For us, Igor will forever remain a devoted, responsive and warm-hearted friend. We will miss him very much, we will always remember him.Elena Belousova on behalf of Russian IBD Study Society and Walter Reinisch on behalf of the organizing committee of Symposium 215 in St. Petersburg.


5

Symposium 215



Start of Registration:Thursday, July 4, 201916 .00 – 21 .00 hat the congress office

Setting Up of Poster Session:Thursday, July 4, 201916 .00 – 21 .00 h

Congress Venue:Park Inn by RadissonPribaltiyskayaUl . Korablestroiteley 14199226 St . PetersburgRussia

Symposium 215 is organized by Falk Foundation e.V.

Scientific Organization:Prof . Dr . Walter ReinischKlinische Abteilung für Gastroenterologie & HepatologieMedizinische Universität WienWähringer Gürtel 18-201090 ViennaAustriaTel .: +43-1-40400-4741Fax: +43-1-40400-4735E-mail: walter .reinisch@meduniwien .ac .at

Scientific Co-Organization:H . Herfarth, Chapel Hill (USA)Y . Shelygin, Moscow (Russia)

Official Language:English .Translation into Russian .


6

Friday, July 5, 2019

9.00 Welcome W . Reinisch, Vienna

Y . Shelygin, Moscow

Session I Epidemiology and translational science inform daily practice

Chair: C . Fiocchi, Cleveland; O . Knyazev, Moscow

9.10 Overview of current IBD epidemiologic E .A . Belousova, and clinical features in Russia Moscow

9.30 Novel immunologic pathways for future therapies in IBD A . Kaser, Cambridge

9.50 How much do genetics and environment determine H . Uhlig, course, behavior and complications of IBD Oxford

10.10 The role of the microbiome - What‘s needed to E .M .M . Quigley, successfully treat dysbiosis in IBD? Houston

10.30 Coffee break with poster session

Session II Diagnostic approaches in IBD

Chair: H . Herfarth, Chapel Hill; I . Zarodnjuk, Moscow

11.00 Fecal and serologic markers – What do they help to M .D . Long, diagnose and predict the course of IBD? Chapel Hill

11.20 Standardized endoscopic scores and their roles in M . Daperno, clinical trials and daily practice Torino

11.40 Imaging in IBD by ultrasound – T . Kucharzik, Current and future perspectives Lüneburg

12.00 The problem of fibrosis in IBD – F . Rieder, Are there diagnostic tools for early detection? Cleveland

12.20 Lunch break with poster session


7

Friday, July 5, 2019 Session III The essential guide to treatment of IBD

Chair: W . Reinisch, Vienna; O . Shifrin, Moscow

14.20 Guide to medical treatment of Crohn’s disease A . Dignass, Frankfurt

14.40 Guide to medical treatment of ulcerative colitis G . Rogler, Zurich

15.00 Important safety aspects of old and new IBD drugs L . Beaugerie, Paris

15.20 IBD therapy: “Next in line, please” S . Schreiber, Kiel


Session IV IBD and the interface of medical and surgical therapy

Chair: F . Carbonnel, Paris; N . Kostenko, Astrakhan

16.10 Surgical standards for Crohn’s disease and W .A . Bemelman, ulcerative colitis Amsterdam

16.30 Treatment approaches for pouchitis H . Herfarth, Chapel Hill

16.50 Therapy of perianal and entero-enteral fistulas – K . Matzel, What‘s standard and what‘s the future? Erlangen

17.10 Postoperative Crohn’s disease management M . Regueiro, Cleveland

17.30 Networking with light refreshments


8

Saturday, July 6, 2019 Session V

IBD: Special situations Chair: I . Bakulin, St . Petersburg; E .A . Belousova, Moscow

9.00 Pregnancy in IBD: What the gastroenterologist C . Dejaco, needs to know Vienna

9.20 Diagnosis and therapy of osteopenia and osteoporosis M . Reinshagen, in IBD Braunschweig

9.40 Frequency of inflammatory bowel diseases G . Lukina, in patients with ankylosing spondylitis Moscow

10.00 PSC, NASH and IBD: What are the facts? M . Trauner, Vienna


Session VI Improving outcomes in IBD

Chair: D . Abdulganieva, Kazan; M . Watanabe, Tokyo

10.50 Presentation of Poster Awards Y . Shelygin, Moscow

11.05 Translation from trials into clinical practice: F . Carbonnel, How to find the right patient Paris

11.25 The clinical value of combination therapies in IBD S . Schreiber, Kiel

11.45 Treatment optimization in IBD W . Reinisch, Vienna

12.05 The dawn of omics: The future of IBD C . Fiocchi, management Cleveland

12.25 Lunch break with poster session


9

Saturday, July 6, 2019 Session VII

Workshops (Case Presentations) 13.30– Workshop 1 14.30 The interdisciplinary path to treatment of ulcerative colitis

Chair: E . Chashkova, Irkutsk; O . Shchukina, St . Petersburg

Panel Discussion: W .A . Bemelman, Amsterdam; M .D . Long, Chapel Hill; W . Reinisch, Vienna

14.30– Workshop 2 15.30 Crohn‘s disease: The interdisciplinary path to treatment

Chair: M . Shapina, Moscow; A . Vardanyan, Moscow

Panel Discussion: K . Matzel, Erlangen; G . Novacek, Vienna


10

Poster Session1. AdherencetotherapyinflammatoryboweldiseaseobservedinMoscow

ClinicalScientificCenter A.Babayan,O.Knyazev,A.I.Parfenov(Moscow,RU)

2. SmallboweladenocarcinomaasararecomplicationofCrohn’sdisease: Acasereport J.Bajor,Z.Szakacs,A.Vincze(Pécs,HU)

3. A2-yearfollow-upstudyassessingbonestatusinchildrenwithinflammatoryboweldiseaseusingdual-energyX-rayabsorptiometry K.Bak-Drabik,A.Zabka,M.Drabik(Zabrze,Katowice,PL)

4. AnalysisofdemographicandclinicalfeaturesofIBDinSaint-Petersburg I.Bakulin,M.Skalinskaya,E.Skazyvaeva,T.Zhigalova,M.Zhuraleva, I.Lapinsky,I.Rasmagina(St.Petersburg,RU)

5. EfficacyandsafetyofthioguanineinIBD A.Bayoumy,A.Ansari(Amsterdam,NL;Redhill,GB)

6. RiskfactorsfordecreasedbonemineraldensityininflammatoryboweldiseaseinaTunisiancohort B.Bouchabou,H.Romdhane,A.Nakhli,N.Hemdani,H.BenNejma, R.Ennaifer(Tunis,TN)

7. Factorsassociatedwothnon-adherencetomedicationforinflammatoryboweldisease:AmonocentricTunesianstudy B.Bouchabou,H.Romdhane,N.Hemdani,A.Nakhli,H.BenNejma, R.Ennaifer(Tunis,TN)

8. Abdominalultrasonographyindifferentialdiagnosisofconcurrentulcerativecolitisanddiverticulardisease A.Chavoushian,A.Petrov,S.Handjiev(Sofia,BG)

9. Extraintestinalmanifestationsininflammatoryboweldisease–Resultsfromaretrospectivestudy C.CijevschiPrelipcean,C.Mihai,M.Dranga,O.Gavrilescu,A.Caroneanu(Iasi,RO)

10. Non-invasiveassessmentofendoscopicactivityinulcerativecolitis C.CijevschiPrelipcean,C.Mihai,O.Gavrilescu,A.Cardoneanu,A.-G.Dorobat,B.Mihai,M.Dranga(Iasi,RO)

11. Anemiaandirondeficiencyininflammatoryboweldisease C.Cojocariu,C.Stanciu,L.Huiban,C.M.Muzica,O.Stoica,I.Girleanu, A.-M.Singeap,Cuciureanu,A.V.Trifan(Iasi,RO)

12. Clinicalpresentationofinflammatoryboweldiseaseinhospitalizedpatients:AretrospectivestudyinatertiarycenterinEasternEurope T.Cuciureanu,L.Huiban,S.Chiriac,O.Petrea,A.-M.Singeap,I.Girleanu,A.V.Trifan(Iasi,RO)

13. Prevalenceandfactorsassociatedwithimpairedfood-relatedqualityoflife:Across-sectionalsurveyof1223peoplewithinflammatoryboweldisease W.Czuber-Dochan,T.Murrells,M.Morgan,M.Lomer,J.O.Lindsay,K.Whelan(London,GB)


11

14. ClinicalfactorspredictiveofCrohn’sdiseasecomplicationsandsurgery O.Daboussi,L.Mouelhi,M.BenKhelifa,K.Eljeri,S.Khedher,M.Salem, Y.Said,R.Dabbech,T.Najjar(Tunis,TN)

15. Featuresofgutdysbiosisinulcerativecolitispatients N.Danilova,M.Markelova,I.Vazherkin,S.Abdulkhakov,T.Grigoryeva, A.Tyakht,A.Pavlenko,A.Odintsova,R.Abdulkhakov(Kazan,Moscow,RU)

16. Ulcerativecolitisinchildren:Fromdiagnosistotreatment R.Despot,E.Runjic,V.Zitko,A.JelicicKadic(Split,Dubrovnik,HR)

17*. SustainabilityofbiologictherapiesislessinUCthanCDpatientsindependentofpriorbiologicexperience J.Doherty,M.Buckley,G.Cullen,D.Keegan,K.Byrne,G.Horgan,H.Mulcahy,J.Sheridan,G.Doherty(Dublin,IE)

18. Oralmanifestationininflammatoryboweldisease M.Drabik,J.Bulka,M.Bulka,K.Bak-Drabik(Gliwice,WegierskaGorka,Zabrze,Katowice,PL)

19. Ulcerativecolitis:Age-relateddifferences M.Dranga,O.Gavrilescu,C.Mihai,C.CijevschiPrelipcean(Iasi,RO)

20. Theuseoffaecalcalprotectinasascreeningtoolforreferralofpatientswithpossibleinflammatoryboweldisease D.Fernandes,S.Mathew,D.Elphick(Chesterfield,GB)

21. ClinicalcharacteristicsofinflammatoryboweldiseaseassociatedtoHyd-radentissupprativa R.Frances,J.Cameo,L.Sempere,A.Gutierrez(Alicante,ES)

22. Microbiotacompositionasapossiblepredictorofinfliximabresponseininflammatoryboweldisease M.Gazouli,N.Dovrolis,G.Michalopoulos,N.-P.Andreou,G.Karamanolis,A.Eliopoulos,G.Kolios(Athens,Alexandroupolis,Piraeus,GR)

23. IntestinalpermeabilityinCrohn‘sdisease:Arethereanyage-relateddifferences? V.Gerova-Nankova,D.Svinarov,S.Stoynov,V.Nakov,L.Tankova,R.Nakov(Sofia,BG)

24. LatenttuberculosisinfectioninIBDpatientsreceivingtreatmentwithanti-TNF-αagentsinanendemicregion C.Gheorghe,A.Dimitriu,M.Cojocaru,R.Costache,L.S.Gheorghe(Bucharest,RO)

25. PsychologicaldistressandsleepdisordersinIBDpatients–Potentialcorrelationswithdiseaseactivity G.-E.Gilca-Blanariu,M.Ciocoiu,G.Stefanescu(Iasi,RO)

26*. EpidemiologyandclinicalcourseofinflammatoryboweldiseaseinRomania:Amulticenter-basedstudy A.Goldis,C.Gheorghe,L.S.Gheorghe,S.Iacob,M.Tantau,C.CijevschiPrelipcean,R.Goldis,M.Diculescu(Timisoara,Bucharest,Cluj-Napoca,Iasi,RO)


12

27. RegionaldifferencesinIBDinRomania R.Goldis,C.Gheorghe,L.S.Gheorghe,S.Iacob,M.Tantau,C.CijevschiPrelipcean,A.Goldis,M.Diculescu(Timisoara,Bukarest,Bucharest,Cluj-Napoca,Iasi,RO)

28. Incidence,endoscopicfeatures,riskfactorsandprognosisofCrohn‘sdiseaseinvolvinguppergastrointestinaltractinChina Y.Gu,J.Zhong(Shanghai,CN)

29. Patientperceptionandapprovaloffecalmicrobiotatransplantation(FMT)asanalternativetreatmentoptionforulcerativecolitis F.Gundling,T.Leimbach,W.Schepp,C.Schuler,S.Roggenbrodt(Munich,DE)

30. EvaluationofCD83withcorrelationbetweenanti-apoptoticmarkersinCrohn’sdisease K.Guzinska-Ustymowicz,W.Ustymowicz,M.Niziol,A.Pryczynicz, J.Zinczuk,K.Zareba,E.Maciorkowska,M.Zakrzewski,M.Maciorkowska(Bialystok,PL)

31. Crohn’sandColitsPregnancyKnowledgescore(CCPknowscore)evaluationinwomenwithinflammatoryboweldisease:PreliminaryresultsofaTunisianstudy N.Hemdani,B.Bouchabou,A.Nakhli,R.Ennaifer,H.BenRomdhane, H.BenNejma(LaMarsa,TN)

32.* WithdrawalofthiopurinesinCrohn’sdiseasetreatedwithscheduledadalimumabmaintenance:Aprospectiverandomisedclinicaltrial(DIAMOND2) T.Hisamatsu,S.Kato,R.Kunisaki,M.Matsuura,M.Nagahori,S.Motoya,M.Esaki,N.Fukata,S.Inoue,T.Sugaya,H.Sakuraba,F.Hirai,K.Watanabe,T.Kanai,M.Naganuma,H.Nakase,Y.Suzuki,M.Watanabe,T.Hibi,‚M.Nojima,T.Matsumoto(Tokyo,Saitama,Kanagawa,Kyoto,Sapporo,Fukuoka,Osaka,Hyogo,Tochigi,Hirosaki,Chikushino,Sakura,Morioka,JP)

33. Therapyexperiencesamongpatientswithinflammatoryboweldisease-relatedirondeficiencyanemia–Areallifestudy L.Huiban,C.Stanciu,C.M.Muzica,O.Stoica,A.-M.Singeap,T.Cuciureanu,C.Cojocariu,A.V.Trifan(Iasi,RO)

34. Correlationoffecalcalprotectinwithclinicalandendoscopicfindingsinpatientswithulcerativecolitis(UC) E.Iglic(Prijedor,BA)

35. TheeffectivenessofcombinationtherapymesenchymalstromalcellsandcertolizumabpegolinperianallesionsinCrohn‘sdisease A.Kagramanova,O.Knyazev,A.Lishchinskaya,M.Zvyaglova, A.Konoplyannikov,A.I.Parfenov(Moscow,Obninsk,RU)

36. In-hospitalprofileofpatientswithinflammatoryboweldiseases A.Kanabayeva,A.V.Nersessov,A.Raissova,A.Kaliyakparova,A.Ualiyeva,J.Kaibullayeva(Almaty,KZ)

37. EfficacyofvaccinationagainsthepatitisAininflammatoryboweldiseasepatients:Asingle-centercohortstudy K.Karmiris,I.Dimas,E.Voudoukis,G.Paspatis(Heraklion,GR)


13

38. FeasibilityoflaparoscopicsurgeryandminimalinvasiveradiologictechnicsinthetreatmentofcomplicationsofCrohn’sdisease S.Kathy,Z.Kincses,D.Toth,P.Kolozsi,Z.Varga(Debrecen,HU)

39. Perceivedacceptabilitytowardslong-termuseoforalnutritionalsupplements(ONS)inadolescentandadultCrohn’sdisease(CD) K.Keetarut,N.Richards,H.Kikuchi,Q.Li,N.Davies,K.Fragkos(London,GB)

40. TheroleofmicroRNAsinS1P-dependendsignalingaxisinadifferentphenotypicpresentationofulcerativecolitisinpatientswithprimarysclerosingcholangitis(PSC) A.Kempinska-Podhorodecka,M.Adamowicz,P.Milkiewicz,M.Milkiewicz(Szczecin,Warsaw,PL)

41. SurgicaltreatmentofCrohn’sdiseasecomplications2009–2018 Z.Kincses,S.Kathy,D.Toth,P.Kolozsi,Z.Varga(Debrecen,HU)

42. Associationbetweenchronicnon-bacterialosteomyelitisandinflammatoryboweldiseaseinchildren,resultfromanationalsurveyoftheSIGENPIBDgroup D.Knafelz,A.Insalaco,S.Arrigo,F.Bracci,V.DiPasquale,E.Felici, P.Lionetti(Rome,Genova,Messina,Alessandria,Florence,IT)

43. GeneexpressionsignatureinCrohn‘sdisease:Novelinsilicoapproachesfordrugrepositioninganddrug-diseaseinteractions G.Kolios,K.Arvanitidis,E.Filidou,L.Kandilogiannakis,I.Drygiannakis, V.Valatas,N.Dovrolis(Alexandroupolis,Heraklion,GR)

44. Short-termandlong-termoutcomesofendoscopicdilatationforCrohn’sdiseasestrictures T.Leimbach,M.Treiber,L.Hartmann,W.Schepp,F.Gundling(Munich,DE)

45. Pathogeneticanddiagnosticsignificanceoftheantibodiestolypopolysac-charideofgutmicrobiotainulcerativecolitis B.N.Levitan,G.Levitan,A.Umerova(Astrakhan,RU)

46. Changesinthehemostaticsysteminpatientswithulcerativecolitisdepen-dingonthedegreeofactivityofthedisease A.Lishchinskaya,O.Knyazev,A.Kagramanova,K.Noskova,V.Subbotin,A.I.Parfenov,G.Dudina(Moscow,RU)

47.* TheincidenceofcancerandmortalityinpediatriconsetinflammatoryboweldiseaseinDenmarkandFinlandduringa23-yearperiod:apopulation-basedstudy M.Malham,C.Jakobsen,A.Paerregaard,L.Virta,K.-L.Kolho,V.Wewer(Copenhagen,DK;Helsinki,Turku,Tampere,FI)

48. Anemiaininflammatoryboweldisease:Isitunderestimated? A.Mehmedovic(Sarajevo,BA)

49.* Intestinalmicrobialsignatureininflammatoryboweldisease C.Mihai,C.CijevschiPrelipcean,M.Dranga,I.Popa,R.C.Popa,I.Bejenariu,A.Cardoneanu(Iasi,RO)

50. Biomarkersandseverityscoresininflammatoryboweldiseases C.Mihai,M.Dranga,O.Gavrilescu,A.Cardoneanu,A.-M.Leustean, A.Lupascu,B.Mihai,C.CijevschiPrelipcean(Iasi,RO)


14

51. AssociationbetweentheIL23RgenepolymorphismandSerbianpatientswithinflammatoryboweldisease D.Mijac,S.Djuranovic,D.Bojic,V.Perovic,D.Popovic,D.Culafic,I.Jovicic,V.Pravica,M.Markovic(Belgrade,RS)

52. Fertility,conceptionanddeliveryinIBDpatients:AretrospectivestudyinaGreekcenter M.Moshovis,I.Zacharopoulou,M.Tzouvala,G.Karamanolis(Athens,GR)

53. AtypicalcutaneousmanifestationofCrohn‘sdisease S.Mrabet,I.Akkari,E.BenJazia(Sousse,TN)

54. PredictingfactorsofsexualdysfunctionamongCrohn‘sdiseasepatients A.Nakhli,M.Sabbah,H.Jlassi,N.Elleuch,D.Trad,H.Elloumi,N.Bibani, A.Ouakaa,D.Gargouri(Tunis,Sousse,TN)

55. AcaseofunusualcutaneoussideeffectduringTNF-alphainhibitortreatmentofIBD? S.Nikolic,B.Luzar,P.B.Marko,I.Holc,C.PernatDrobez,A.Ocepek(Maribor,Ljubljana,SI)

56. Regionalsurveyonpsychosocialaspectsoflivingwithinflammatoryboweldisease:Patients’perspective V.OrsicFric,V.Borzan,B.Borzan(Osijek,HR)

57. Stoma-relatedcomplicationsafterilealpouch-analanastomosisinulcerativecolitis I.Papaconstantinou,G.Karamanolis,A.Gklavas,D.Dellaportas(Athens,GR)

58. Cardiovascularassessmentinpatientswithinflammatoryboweldisease I.Papaconstantinou(Athens,GR)

59. ComparativefrequencyofClostridialinfectioninpatientswithulcerativecolitisreceivingmesenchymalstromalcellsandbiologicalpreparations A.I.Parfenov,O.Knyazev,M.Chernova(Moscow,RU)

60. Azathioprineasamonotherapyorincombinationwith5-aminosalicylatesinpatientswithinflammatoryboweldiseaseinachievingbettertherapeuticresponse K.Pavlovska,M.SlaninkaMiceska,M.Petrushevska,E.Atanasovska, I.Kikerkov,P.Mishevska,V.Andreevski,V.Avramovski,J.TonicRibarska(Skopje,MK)

61. Arthropathiesinulcerativecolitis:Variousclinicaltypes O.Petrascu,A.B.Boicean(Sibiu,RO)

62. Urolithiasisasanextraintestinalmanifestationofinflammatoryboweldiseaseinatertiaryreferralcenter O.Petrea,A.V.Trifan,I.Girleanu,A.-M.Singeap,C.Cojocariu,L.Huiban,C.Stanciu(Iasi,RO)

63.* TheroleofcapsuleendoscopyinevaluatingsmallbowelinvolvementinpatientswithperianalCrohn‘sdisease C.Pontas,N.Viazis,C.Hantzievangelinou,F.Gkeros,G.Filipidis, G.Karampekos,M.Vraka,A.Tsatsa,E.Vienna,G.J.Mantzaris(Athens,GR)


15

64. Cholestatichepatitisprecedingtheappearanceofcolitisintwoboys J.Porebska,A.Porebski,A.Chobot(Zabrze,Opole,PL)

65. ThelevelsofvitaminDinchildrenwithaninflammatoryboweldiseaseduringthe year A.S.Potapov,H.Simikina,V.Tsvetkova,O.Melnichuk,A.Illarionov, A.Anoushenko(Moscow,RU)

66. CorrelationbetweenendoscopicindexofdiseaseacitivityandvaluesofCRPinIBDpatients G.Predojevic(Prijedor,BA)

67. ExpressionofsurvivinandPCNAproteinsininflammatoryboweldiseases A.Pryczynicz,M.Niziol,J.Zinczuk,K.Zareba,W.Ustymowicz,K.Guzinska-Ustymowicz(Bialystok,PL)

68. TreatmentofinducedcolitisinmicebytheRasantagonistfarnesylthiosalicylicacid(FTS) S.Reif,T.Oron,D.Rachmilewitz,R.Haklai,Y.Kloog(Jerusalem,TelAviv,IL)

69. Casereport:TelogeneffluviumasthefirstsympotofCrohn‘sdiseaseinachild M.Rogalidou,T.Palianopoulos,K.Katsanos,D.Christodoulou,G.Gaitanis,A.Zioga,N.Haliasos(Ioannina,GR)

70. CD83+dendriticcells(DC)inCrohn’sdisease(CD)andulcerativecolitis(UC) B.RosicDespalatovic,A.Bratanic,M.Babic,K.Vilovic,A.Tonkic(Split,HR)

71. Long-termobservationofthehumangutmicrobiotadiversitychangesaftertheHelicobacterpylorieradicationtherapy D.Safina,M.Markelova,T.Grigoryeva,S.Abdulkhakov,E.Boulygina, S.Malanin,I.Vasilyev,M.Siniagina,R.Abdulkhakov(Kazan,RU)

72. Acuteeosinophilicpneumoniarelatedtoamesalazineusageinpediatricpatient–Casereport M.Samma,I.Pukite(Riga,LV)

73. 30-daymortalityfollowingendoscopyinPrinceCharlesHospital S.Shwana,D.Taha(MerthyrTydfil,Cardiff,GB)

74.* GutbarrierfailurebiomarkersinIBD:Isthereanythingnewbeyond‚‘TheWall‘‘? N.Sipeki,P.Kovacs,B.Balogh,Z.Shums,G.L.Norman,P.Antal-Szalmas,M.Papp(Debrecen,HU;SanDiego,US)

75. ThecomplexityofthedifferentialdiagnosisofIBD:MimicryEntamebahistolytica M.Skalinskaya,I.Bakulin,E.Skazyvaeva,I.Belyakov,S.Vorobyev (St.Petersburg,RU)

76. EmbeddingpharmaceuticalcareintotheIBDmultidisciplinaryteam A.St.ClairJones(Brighton,GB)

77. PharmacyTechnicianintheIBDteammaintainspatientsafetywhilstfreeinguppharmacistsandphysicians A.St.ClairJones,A.Packham(Brighton,GB)

78. Biologicaltherapyreducestheneedforintravenousironsupplementationinpatientswithinflammatoryboweldisease Z.Sundov,I.Zaja,A.Krizman(Split,HR)


16

79. LaparoscopicileocolicresectionforfibrostenoticandcomplexCrohn’sdisease G.Theodoropoulos,N.Kourikou,P.Pantsas,A.Mika,S.Manolakopoulos,G.Zografos(Athens,GR)

80. Smallbowelcapsuleendoscopy:Avaluabletoolforclassifyingtheunclassified A.V.Trifan,A.-M.Singeap,I.Girleanu,T.Cuciureanu,C.Stanciu(Iasi,RO)

81. ParticularitiesoftherapeuticstrategiesinIBDpatientsfromNorth-EasternRomania A.V.Trifan,O.Petrea,I.Girleanu,C.Sfarti,C.Cojocariu,L.Huiban,C.Muzica,C.Stanciu(Iasi,RO)

82. CorrelationbetweenKi67expressionwithFas/FasLexpressionsinIBDpatients W.Ustymowicz,M.Niziol,A.Pryczynicz,J.Zinczuk,K.Zareba, E.Maciorkowska,M.Zakrzewski,M.Maciorkowska,K.Guzinska-Ustymowicz(Bialystok,PL)

83. Listeriamonogytogenesmeningitisinapatientwithulcerativecolitisusinginfliximab:Acasereport A.Uyanikoglu,C.Cindoglu,A.Konca(Sanliurfa,TR)

84. IshepatitisBandhepatitisCscreeningbeingneglectedinpatientswithinflammatoryboweldisease?Whatisthefrequency? A.Uyanikoglu,A.Ciftci,N.Yenice(Sanliurfa,TR)

85. Efficacyofinfliximabafterfailureofsubcutaneousanti-TNFagentsinpatientswithmoderate-to-severeulcerativecolitis N.Viazis,E.Tsoukali,M.Galanopoulos,C.Pontas,O.Giouleme, G.Theocharis,M.Tzouvala,E.Archavlis,A.Christidou,G.J.Mantzaris(Athens,Thessaloniki,Patras,GR)

86. Phenotypeofinflammatoryboweldiseaseinpatientsonbiologicaltherapy L.Vranic,S.Milic,D.Stimac,B.MijandrusicSincic(Rijeka,HR)

87. Azathioprinedosingandmetabolitemeasurementinpaediatricinflammatoryboweldisease–Doesonesizefitall? R.Walker,J.Kammermeier,R.Vora,M.Mutalib(London,GB)

88.* CandailySCCAImeasurementsovera6monthperiodbetterphenotypethepatternofdiseaseinulcerativecolitis? A.Walsh,A.Kormilitzin,C.Hinds,V.Sexton,O.Brain,S.Keshav,H.Uhlig,J.Geddes,G.Goodwin,G.Collins,S.P.L.Travis(Oxford,GB)

89. AnalysisoffungalmicrobiotadysbiosisinIBD Y.Wang,M.Zhuo,L.Zeng(Chengdu,CN)

90. TheimpactofsurgicalresectiononbonelossinpatientswithCrohn’sdisease Y.Yin,L.Cao,R.Liu,L.Huang,Y.Li,W.Zhu(Nanjing,CN)

91. Long-termfollow-upofagirlwithco-occurrenceofceliacdiseaseandulcerativecolitis O.Zaja,B.Perse,A.Kovacevic,Q.Kaurich(Zagreb,HR;Bloomington,US)


17

92. Correlationbetweencaspase-8andsurvivinexpressioninpatientswithulcerativecolitis J.Zinczuk,K.Zareba,M.Niziol,W.Ustymowicz,K.Guzinska-Ustymowicz,J.Matowicka-Karna,A.Pryczynicz(Bialystok,PL)

93. Smallintestinalbacterialovergrowthinpatientswithinflammatoryboweldisease:Genderandagepeculiarities E.Zyhalo,L.Demeshkina,M.Stoykevich(Dnipropetrovsk,UA)

*=PostersofDistinction


18

List of Speakers, Moderators and Scientific Organizers

Dr. Diana AbdulganievaDepartment of Internal MedicineKazan State Medical UniversityButlerov Str . 49420012 KazanRussiadiana_s@mail .ru

Prof. Dr. Igor BakulinDepartment of Internal Diseases, Gastroenterology and DietologyNorth-Western State Medical University named after I .I . Mechnikov Kirochnaya ul . 41191015 St . PetersburgRussiaigbakulin@yandex .ru

Prof. Dr. Laurent BeaugerieDepartment of GastroenterologyHôpital Saint Antoine184, Rue du Faubourg St .-Antoine75012 ParisFrancelaurent .beaugerie@sat .aphp .fr

Prof. Dr. Elena A. BelousovaMoscow Regional ResearchClinical InstituteUl . Tschepkina 61/2-5129110 MoscowRussiaeabelous@yandex .ru

Prof. Dr. Willem A. BemelmanDepartment of SurgeryTytgat Institute for Liver & Intestinal ResearchUniversity of AmsterdamMeibergdreef 91105 AZ AmsterdamThe Netherlandsw .a .bemelman@amc .uva .nl

Prof. Dr. Franck CarbonnelService d‘Hépatogastroentérologie78 rue du Général Leclerc94275 Le Kremlin BicetreFrancefranck .carbonnel@bct .aphp .fr

Dr. Elena ChashkovaDepartment of Reconstructive SurgeryIrkutsk Scientific Center for Surgery and TraumatologyDistrict of the Jubilee 100664002 IrkutskRussiaelenachash1027@yandex .ru

Dr. Marco DapernoGastroenterology UnitMauriziano HospitalLargo Turati 6210128 TorinoItalymdaperno@gmail .com

Prof. Dr. Clemens DejacoKlinische Abteilung für Gastroenterologie & HepatologieMedizinische Universität WienWähringer Gürtel 18-201090 ViennaAustriaclemens .dejaco@meduniwien .ac .at

Prof. Dr. Axel DignassMedizinische Klinik IAGAPLESIONMarkus KrankenhausWilhelm-Epstein-Str . 460431 FrankfurtGermanyaxel .dignass@fdk .info


19

Claudio Fiocchi, M.D.Professor of MedicineDepartment of Inflammation and Immunity / NC2Lerner Research InstituteThe Cleveland Clinic Foundation9500 Euclid AvenueCleveland, OH 44195USAfiocchc@ccf .org

Hans Herfarth, M.D.Professor of MedicineGastroenterology and HepatologyUniversity of North Carolina4151 Bioinformatics Bldg .130 Mason Farm RoadChapel Hill, NC 27599-7080USAhherf@med .unc .edu

Prof. Dr. Arthur KaserDivision of Gastroenterology & HepatologyAddenbrooke‘s HospitalUniversity of CambridgeHills RoadCambridge CB2 0QQGreat Britainak729@cam .ac .uk

Dr. Oleg KnyazevDepartment of GastroenterologyMoscow Clinical Scientific CenterShosse Enthuziastov, 86 111123 Moscow Russiaknyazev-oleg@yandex .ru

Dr. Nikolay KostenkoDepartment of SurgeryAstrakhan State Medical University Bakinskaya St . 121 414000 AstrakhanRussiakostenki@mail .ru

Prof. Dr. Torsten KucharzikInnere Medizin/GastroenterologieKlinikum LüneburgBögelstr . 121339 LüneburgGermanytorsten .kucharzik@klinikum-lueneburg .de

Millie D. Long, M.D.Associate Professor of MedicineDivision of Gastroenterologyand HepatologyUniversity of North Carolina4147 Bioinformatics Bldg .130 Mason Farm RoadChapel Hill, NC 27599-7080USAmillie_long@med .unc .edu

Prof. Dr. Galina LukinaDepartment of RheumatologyMoscow Clinical Scientific CenterShosse Enthuziastov, 86 111123 MoscowRussiagvl3@yandex .ru

Prof. Dr. Klaus MatzelSektion KoloproktologieUniversitätsklinikum ErlangenKrankenhausstr . 1291054 ErlangenGermanyklaus .matzel@uk-erlangen .de

Prof. Dr. Gottfried NovacekKlinische Abteilung für Gastroenterologie & HepatologieMedizinische Universität WienWähringer Gürtel 18-201090 ViennaAustriagottfried .novacek@meduniwien .ac .at


20

Eamonn M.M. Quigley, M.D.Professor of MedicineGastroenterology and HepatologyHouston Methodist Hospital, SM12016550 Fannin St .Houston, TX 77030USAequigley@houstonmethodist .org

Prof. Dr. Walter ReinischKlinische Abteilung fürGastroenterologie & HepatologieMedizinische Universität WienWähringer Gürtel 18-201090 ViennaAustriawalter .reinisch@meduniwien .ac .at

Prof. Dr. Max ReinshagenKlinik für Magen- und DarmerkrankungenInnere Medizin IStädtisches Klinikum BraunschweigSalzdahlumer Str . 9038126 BraunschweigGermanym .reinshagen@klinikum-braunschweig .de

Miguel Regueiro, M.D.Professor of MedicineDepartment of Gastroenterology and HepatologyLerner College of Medicine Cleveland Clinic 9500 Euclid AvenueCleveland, OH 44195USAregueim@ccf .org

Florian Rieder, M.D.Department of Pathology, NC22The Cleveland Clinic FoundationLerner Research Institute9500 Euclid AvenueCleveland, OH 44195USAriederf@ccf .org

Prof. Dr. Dr. Gerhard RoglerKlinik für Gastroenterologie& HepatologieUniversitätsspital ZürichRämistr . 1008091 ZürichSwitzerlandgerhard .rogler@usz .ch

Prof. Dr. Stefan SchreiberKlinik für Innere Medizin IUniversitätsklinikumSchleswig-Holstein, Campus KielArnold-Heller-Str . 3 (Haus 6)24105 KielGermanys .schreiber@mucosa .de

Dr. Marina ShapinaDepartment of GastroenterologyState Scientific Center of ColoproctologySalyam Adyl Str . 2123423 MoscowRussiashapina .mv@yandex .ru

Prof. Dr. Yury ShelyginState Scientific Center of ColoproctologySalyam Adyl Str . 2123423 MoscowRussiashelygin@yandex .ru

Prof. Dr. Oleg ShifrinDepartment of GastroenterologySechenov First Moscow State Medical University8-2, Trubetskaya St .119991 MoscowRussiaoleg_shifrin@mail .ru

Dr. Oksana ShchukinaCity Clinical Hospital No 313 Dinamo Pr . 197110 St . PetersburgRussiaburmao@gmail .com


21

Prof. Dr. Michael TraunerKlinische Abteilung fürGastroenterologie & HepatologieMedizinische Universität WienWähringer Gürtel 18-201090 ViennaAustriamichael .trauner@meduniwien .ac .at

Prof. Dr. Holm UhligJohn Radcliffe HospitalNHS TrustHeadley Way HeadingtonOxford OX3 9DUGreat Britainholm .uhlig@ndm .ox .ac .uk

Dr. Armen VardanyanDepartment of SurgeryState Scientific Center of ColoproctologySalyam Adyl Str . 2123423 MoscowRussiaarmvard@yandex .ru

Prof. Dr. Mamoru WatanabeDepartment of GastroenterologySchool of MedicineTokyo Medical & Dental University1-5-45, Yushima, Bunkyo-kuTokyo 113-8519Japanmamoru .gast@tmd .ac .jp

Dr. Irina ZarodnjukDepartment of RadiologyState Scientific Center of ColoproctologySalyam Adyl Str . 2123423 MoscowRussia89104420581@mail .ru


22

Congress OfficeDuring Symposium 215

Congress Office Telephone: +49-175-7795-327

Opening Hours:Thursday, July 4, 2019 16 .00 – 21 .00 hFriday, July 5, 2019 8 .00 – 17 .30 hSaturday, July 6, 2019 8 .30 – 15 .30 h

Park Inn by RadissonPribaltiyskayaUl . Korablestroiteley 14199226 St . PetersburgRussia

Congress FeesScientific Program of Symposium 215 EUR 200Students (copy of student ID required) EUR 100

***OR***

Day Ticket EUR 120Students (copy of student ID required) EUR 60

The congress fees include:- Pre-Opening and Welcome on Thursday, July 4, 2019- Refreshments during coffee breaks- Lunch on July 5 and on July 6, 2019- Light Refreshments during Networking on Friday, July 5, 2019- A copy of the abstract volume- A copy of the final program


23

Admission to Scientific ProgramFor admission to scientific events your name badge should be clearly visible .Accompanying persons are not permitted during the Conference at any time .

AirportPulkovo AirportDistance to Hotel: Approx . 30 km, travel time approx . 20-30 min .

Train StationMoskovsky Railway StationDistance to Hotel: Approx . 10 km, travel time approx . 60 min .

Metro-StationPrimorskaya Metro Station is approximately 1,5 km away

Conflicts of InterestMembers of the scientific committee declare the following potential conflicts of interest:

Hans Herfarth: Pfizer, Artizan, Alivio, Amag, Boehringer Ingelheim, Merck, Seres, Celltrion, Finch, Gilead, Lycera; Walter Reinisch: Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmbH, Bioclinica, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Janssen, Johnson & Johnson, Kyowa, Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tababe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, Otsuka , Parexel, PDL, Periconsulting, Pharma-cosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Robasts Clinical Trail , Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Takeda, Therakos, Tigenix, UCB, Vifor, Zealand, Zyngenia and 4SC; Igor Shelygin: declares no conflicts of interest .


2019

International Symposiaand Workshops

Scientific Dialogue in the Interest of Therapeutic Progress

Symposium 216Building Bridges in IBDBrussels, BelgiumSeptember 13–14, 2019

Symposium 217West Meets East:Functional Meets OrganicGastrointestinal DiseasesSingaporeNovember 29–30, 2019

WorkshopFrom Viral Hepatitis to ChronicInflammation and Liver CancerHeidelberg, GermanyFebruary 21–22, 2019

Symposium 214IBD: From Pathophysiologyto Personalized MedicineOxford, Great BritainMarch 29–30, 2019

Symposium 215IBD: From Diagnosis to TherapySt. Petersburg, RussiaJuly 5–6, 2019

Congress DepartmentTel.: +49 (0)761/1514-125Fax: +49 (0)761/1514-359E-Mail: symposia@falk-foundation-symposia.orgwww.falk-foundation-symposia.org



252019

International Symposia and Workshops

Scientific Dialoguein the Interest of

Therapeutic Progress

Symposium 216Building Bridges in IBDBrussels, BelgiumSeptember 13–14, 2019

Symposium 217West Meets East:Functional Meets Organic Gastrointestinal DiseasesSingaporeNovember 29–30, 2019

WorkshopFrom Viral Hepatitis to ChronicInflammation and Liver CancerHeidelberg, GermanyFebruary 21–22, 2019

Symposium 214IBD: From Pathophysiology to Personalized MedicineOxford, Great BritainMarch 29–30, 2019

Symposium 215IBD: From Diagnosis to TherapySt. Petersburg, RussiaJuly 5–6, 2019




Symposium 215



Program

P215

1-5

/201

9/1

.10

0 St

ü

Application for CME credits submitted

Organized by:

FALK FOUNDATION e.V.Leinenweberstr. 579108 FreiburgGermany

Congress DepartmentTel.: +49–761–1514–125Fax: +49–761–1514–359E-Mail: symposia@falk-foundation-symposia.orgwww.falk-foundation-symposia.org

20414_Falk_St_Petersburg_Symp_215_Prog_UG.indd 1 20.05.19 09:55

Germany Program · 2019-05-23 · Program P215 1-5/2019/1.100 Stü ... Igor will forever remain a...

Documents

Transcript of Germany Program · 2019-05-23 · Program P215 1-5/2019/1.100 Stü ... Igor will forever remain a...